HKUCTR-2806
Untitled Trial
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)
AstraZeneca Hong Kong Limited·Phase 3·HKU CLINICAL TRIALS REGISTRY·drugNot yet recruiting
Study focus
- Disease/Condition
- Neoplasm
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- AstraZeneca Hong Kong Limited
- Location
- China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- N/A
- End date
- Oct 31, 2020
ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2806
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2806 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca Hong Kong Limited and is currently Not yet recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.